Neurogene

Update in progress

NGNE (NasdaqGM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Neurogene Inc. is a clinical-stage biotechnology company focused on genetic medicines for rare neurological diseases. Its candidates include NGN-401, an AAV9-delivered therapy in Phase 1/2 for Rett syndrome, and NGN-101, a conventional gene therapy in Phase 1/2 for CLN5 Batten disease. The company has licenses with University of Edinburgh, Virovek, Sigma-Aldrich, and Stanford. Founded in 2018, headquartered in New York, NY.

Company score

Sentiment: -0.02; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: -0.15; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.19; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.08; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: -0.05; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive